Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?

Duran, Goretti; Cruz, Raquel; Simões, Ana Rita; Barros, Francisco; Giráldez, José María; Bernárdez, Beatriz; Anido, Urbano; Candamio, Sonia; López‐López, Rafael; Carracedo, Ángel; Lamas, María Jesús

doi:10.1080/1120009x.2020.1764281

Cited by 8 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, neoadjuvant drug therapies prior to surgery help ensure a contained population of cancer cells, and adjuvant drug therapies after surgery aim to eliminate undetectable surviving fragments of the primary tumor or micrometastases elsewhere in the body. Both neoadjuvant and adjuvant therapies can be improved based on genetic and molecular markers of the cancer cells' state and heterogeneity (Dressman et al, 2006;Duran et al, 2020;Oshi et al, 2020). Upon detection or at the start of a management program, complete elimination of an invasive species often succeeds or fails based on the ability to find and cull all individuals.…”

Section: The Illusive Universal Predictor Of Invasive Potential-management Issuesmentioning

confidence: 99%

The Genomic Processes of Biological Invasions: From Invasive Species to Cancer Metastases and Back Again

et al. 2021

View full text Add to dashboard Cite

The concept of invasion is useful across a broad range of contexts, spanning from the fine scale landscape of cancer tumors up to the broader landscape of ecosystems. Invasion biology provides extraordinary opportunities for studying the mechanistic basis of contemporary evolution at the molecular level. Although the field of invasion genetics was established in ecology and evolution more than 50 years ago, there is still a limited understanding of how genomic level processes translate into invasive phenotypes across different taxa in response to complex environmental conditions. This is largely because the study of most invasive species is limited by information about complex genome level processes. We lack good reference genomes for most species. Rigorous studies to examine genomic processes are generally too costly. On the contrary, cancer studies are fortified with extensive resources for studying genome level dynamics and the interactions among genetic and non-genetic mechanisms. Extensive analysis of primary tumors and metastatic samples have revealed the importance of several genomic mechanisms including higher mutation rates, specific types of mutations, aneuploidy or whole genome doubling and non-genetic effects. Metastatic sites can be directly compared to primary tumor cell counterparts. At the same time, clonal dynamics shape the genomics and evolution of metastatic cancers. Clonal diversity varies by cancer type, and the tumors’ donor and recipient tissues. Still, the cancer research community has been unable to identify any common events that provide a universal predictor of “metastatic potential” which parallels findings in evolutionary ecology. Instead, invasion in cancer studies depends strongly on context, including order of events and clonal composition. The detailed studies of the behavior of a variety of human cancers promises to inform our understanding of genome level dynamics in the diversity of invasive species and provide novel insights for management.

show abstract

Section: The Illusive Universal Predictor Of Invasive Potential-management Issuesmentioning

confidence: 99%

The Genomic Processes of Biological Invasions: From Invasive Species to Cancer Metastases and Back Again

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, the administration of these medicines, has been linked to adverse effects, such as vomiting, hair loss and nausea and not demonstrated the expected efficacy. 8 Variety of drawbacks also associated with anticancer drugs, such as hydrophobicity, low water solubility, inadequate biodistribution, and susceptibility to multiple drug resistance. 9 This has urged the need for innovative approaches to enhance the physicochemical and pharmacodynamic properties of standard chemotherapeutics, or achieve target-specific delivery to optimise treatment effectiveness while reducing off-target side effects.…”

Section: Introductionmentioning

confidence: 99%

Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment

Choukaife¹,

Seyam²,

Alallam³

et al. 2022

IJN

View full text Add to dashboard Cite

As per the WHO, colorectal cancer (CRC) caused around 935,173 deaths worldwide in 2020 in both sexes and at all ages. The available anticancer therapies including chemotherapy, radiotherapy and anticancer drugs are all associated with limited therapeutic efficacy, adverse effects and low chances. This has urged to emerge several novel therapeutic agents as potential therapies for CRC including synthetic and natural materials. Orally administrable and targeted drug delivery systems are attractive strategies for CRC therapy as they minimize the side effects, enhance the efficacy of anticancer drugs. Nevertheless, oral drug delivery till today faces several challenges like poor drug solubility, stability, and permeability. Various oral nano-based approaches and targeted drug delivery systems have been developed recently, as a result of the ability of nanoparticles to control the release of the encapsulant, drug targeting and reduce the number of dosages administered. The unique physicochemical properties of chitosan polymer assist to overcome oral drug delivery barriers and target the colon tumour cells. Chitosan-based nanocarriers offered additional improvements by enhancing the stability, targeting and bioavailability of several anti-colorectal cancer agents. Modified chitosan derivatives also facilitated CRC targeting through strengthening the protection of encapsulant against acidic and enzyme degradation of gastrointestinal track (GIT). This review aims to provide an overview of CRC pathology, therapy and the barriers against oral drug delivery. It also emphasizes the role of nanotechnology in oral drug targeted delivery system and the growing interest towards chitosan and its derivatives. The present review summarizes the relevant works to date that have studied the potential applications of chitosan-based nanocarrier towards CRC treatment.

show abstract

“…Adjuvant chemotherapeutics such as oxaliplatin combined with 5-FU or capecitabine are the standard adjuvant chemotherapy for CC ( Lund et al, 2016 , Soveri et al, 2019 ). However, oxaliplatin is known to induce neurotoxicity that causes hyper-excitation of axons resulting in oxidative stress and neuronal damage ( Soveri et al, 2019 , Duran et al, 2020 ). In addition, 5-FU also causes unpleasant side effects such as cardiotoxicity, alopecia, bone marrow suppression, which results in neutropenia and inability to fight infections, and gastro-intestinal upsets, including stomatitis, vomiting, nausea, and diarrhoea ( Opattova et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Effect of lycopene as an adjuvant therapy with 5-florouracil in human colon cancer

Alhoshani

AL–Johani

Alkeraishan

et al. 2022

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?

Cited by 8 publications

References 42 publications

The Genomic Processes of Biological Invasions: From Invasive Species to Cancer Metastases and Back Again

The Genomic Processes of Biological Invasions: From Invasive Species to Cancer Metastases and Back Again

Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment

Effect of lycopene as an adjuvant therapy with 5-florouracil in human colon cancer

Contact Info

Product

Resources

About